Literature DB >> 33640015

Elucidating the cellular mechanism for E2-induced dermal fibrosis.

DeAnna Baker Frost1, Alisa Savchenko2, Adeyemi Ogunleye3, Milton Armstrong4, Carol Feghali-Bostwick2.   

Abstract

BACKGROUND: Both TGFβ and estradiol (E2), a form of estrogen, are pro-fibrotic in the skin. In the connective tissue disease, systemic sclerosis (SSc), both TGFβ and E2 are likely pathogenic. Yet the regulation of TGFβ in E2-induced dermal fibrosis remains ill-defined. Elucidating those regulatory mechanisms will improve the understanding of fibrotic disease pathogenesis and set the stage for developing potential therapeutics. Using E2-stimulated primary human dermal fibroblasts in vitro and human skin tissue ex vivo, we identified the important regulatory proteins for TGFβ and investigated the extracellular matrix (ECM) components that are directly stimulated by E2-induced TGFβ signaling.
METHODS: We used primary human dermal fibroblasts in vitro and human skin tissue ex vivo stimulated with E2 or vehicle (ethanol) to measure TGFβ1 and TGFβ2 levels using quantitative PCR (qPCR). To identify the necessary cell signaling proteins in E2-induced TGFβ1 and TGFβ2 transcription, human dermal fibroblasts were pre-treated with an inhibitor of the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathway, U0126. Finally, human skin tissue ex vivo was pre-treated with SB-431542, a TGFβ receptor inhibitor, and ICI 182,780, an estrogen receptor α (ERα) inhibitor, to establish the effects of TGFβ and ERα signaling on E2-induced collagen 22A1 (Col22A1) transcription.
RESULTS: We found that expression of TGFβ1, TGFβ2, and Col22A1, a TGFβ-responsive gene, is induced in response to E2 stimulation. Mechanistically, Col22A1 induction was blocked by SB-431542 and ICI 182,780 despite E2 stimulation. Additionally, inhibiting E2-induced ERK/MAPK activation and early growth response 1 (EGR1) transcription prevents the E2-induced increase in TGFβ1 and TGFβ2 transcription and translation.
CONCLUSIONS: We conclude that E2-induced dermal fibrosis occurs in part through induction of TGFβ1, 2, and Col22A1, which is regulated through EGR1 and the MAPK pathway. Thus, blocking estrogen signaling and/or production may be a novel therapeutic option in pro-fibrotic diseases.

Entities:  

Keywords:  Dermal fibroblasts; Estradiol; Fibrosis; Skin; TGFβ

Mesh:

Substances:

Year:  2021        PMID: 33640015      PMCID: PMC7913437          DOI: 10.1186/s13075-021-02441-x

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


  54 in total

1.  Gender-based differences in bleomycin-induced pulmonary fibrosis.

Authors:  Mehrnaz Gharaee-Kermani; Kazuo Hatano; Yasuhiro Nozaki; Sem H Phan
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

2.  Regulation of the transforming growth factor-beta 1 and -beta 3 promoters by transcription factor Sp1.

Authors:  A G Geiser; K J Busam; S J Kim; R Lafyatis; M A O'Reilly; R Webbink; A B Roberts; M B Sporn
Journal:  Gene       Date:  1993-07-30       Impact factor: 3.688

3.  Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis?

Authors:  M Gruschwitz; P U Müller; N Sepp; E Hofer; A Fontana; G Wick
Journal:  J Invest Dermatol       Date:  1990-02       Impact factor: 8.551

4.  Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis.

Authors:  Thanh-Thuy T Le; Harry Karmouty-Quintana; Ernestina Melicoff; Thanh-Truc T Le; Tingting Weng; Ning-Yuan Chen; Mesias Pedroza; Yang Zhou; Jonathan Davies; Kemly Philip; Jose Molina; Fayong Luo; Anuh T George; Luis J Garcia-Morales; Raquel R Bunge; Brian A Bruckner; Matthias Loebe; Harish Seethamraju; Sandeep K Agarwal; Michael R Blackburn
Journal:  J Immunol       Date:  2014-08-29       Impact factor: 5.422

5.  Characterization of type I receptors for transforming growth factor-beta and activin.

Authors:  P ten Dijke; H Yamashita; H Ichijo; P Franzén; M Laiho; K Miyazono; C H Heldin
Journal:  Science       Date:  1994-04-01       Impact factor: 47.728

6.  Immunohistochemical localization of intracellular and extracellular associated TGF beta in the skin of patients with systemic sclerosis (scleroderma) and primary Raynaud's phenomenon.

Authors:  A Gabrielli; C Di Loreto; R Taborro; M Candela; P Sambo; C Nitti; M G Danieli; F DeLustro; J R Dasch; G Danieli
Journal:  Clin Immunol Immunopathol       Date:  1993-09

7.  Brief Report: Whole-Exome Sequencing for Identification of Potential Causal Variants for Diffuse Cutaneous Systemic Sclerosis.

Authors:  Angel C Y Mak; Paul L F Tang; Clare Cleveland; Melanie H Smith; M Kari Connolly; Tamiko R Katsumoto; Paul J Wolters; Pui-Yan Kwok; Lindsey A Criswell
Journal:  Arthritis Rheumatol       Date:  2016-09       Impact factor: 10.995

8.  STAT3 controls COL1A2 enhancer activation cooperatively with JunB, regulates type I collagen synthesis posttranscriptionally, and is essential for lung myofibroblast differentiation.

Authors:  Ioannis Papaioannou; Shiwen Xu; Christopher P Denton; David J Abraham; Markella Ponticos
Journal:  Mol Biol Cell       Date:  2017-11-15       Impact factor: 4.138

9.  A Human Skin Model Recapitulates Systemic Sclerosis Dermal Fibrosis and Identifies COL22A1 as a TGFβ Early Response Gene that Mediates Fibroblast to Myofibroblast Transition.

Authors:  Tomoya Watanabe; DeAnna Baker Frost; Logan Mlakar; Jonathan Heywood; Willian A da Silveira; Gary Hardiman; Carol Feghali-Bostwick
Journal:  Genes (Basel)       Date:  2019-01-22       Impact factor: 4.096

10.  Estrogen Regulates MAPK-Related Genes through Genomic and Nongenomic Interactions between IGF-I Receptor Tyrosine Kinase and Estrogen Receptor-Alpha Signaling Pathways in Human Uterine Leiomyoma Cells.

Authors:  Linda Yu; Alicia B Moore; Lysandra Castro; Xiaohua Gao; Hoang-Long C Huynh; Michelle Klippel; Norris D Flagler; Yi Lu; Grace E Kissling; Darlene Dixon
Journal:  J Signal Transduct       Date:  2012-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.